Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database
Open Access
- 1 January 2018
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 17
Abstract
Stereotactic body radiotherapy (SBRT) is widely used as a curative treatment option for stage I non-small-cell lung cancer, but for patients with stage I small-cell lung cancer, the role of stereotactic body radiotherapy is unclear. In this study, we retrospectively analyzed the outcomes of a subset of patients with stage I small-cell lung cancer treated with stereotactic body radiotherapy in the database of the Japanese Radiological Society-Multi-Institutional stereotactic body radiotherapy Study Group. The 43 patients treated with stereotactic body radiotherapy for stage I small-cell lung cancer between 2004 and 2012 at 11 Japanese institutions were studied: median age = 77 years; 32 (74%) males and 11 females; and 80% were medically inoperable. The clinical stage was IA in 31 and IB in 12. In all patients, the lung tumors were pathologically proven as small-cell lung cancer. A total dose of 48 to 60 Gy was administered in 4 to 8 fractions. The median biologically effective dose (α/β = 10 Gy) was 105.6 Gy. Chemotherapy and prophylactic cranial irradiation were administered in only 8 patients, respectively. The median follow-up time was 23.2 months. The 2-year overall survival, progression-free survival, and distant metastasis-free survival rates were 72.3%, 44.6%, and 47.2%, respectively. The 2-year local control was 80.2%. Regarding the patterns of failure, distant metastasis, lymph node metastasis, and local recurrence were observed in 47%, 28%, and 16% of patients, respectively. No ≥grade 3 stereotactic body radiotherapy-related toxicities were observed. Although stereotactic body radiotherapy was thus revealed to be effective for the local control of stage I small-cell lung cancer, the incidence of distant metastases was high. Further investigations of larger cohorts are needed, including analyses of the effects of combined chemotherapy.Keywords
Funding Information
- Japan Society for the Promotion of Science (JSPS) Kakenhi (JP16H05389)
This publication has 31 references indexed in Scilit:
- Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experienceJournal of Radiation Research, 2012
- Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?Cancer, 2009
- Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trialThe Lancet Oncology, 2009
- Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has comeThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Small cell lung cancer in Norway. Should more patients have been offered surgical therapy?European Journal of Cardio-Thoracic Surgery, 2004
- A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2004
- Sex differences in survival in non-small cell lung cancer patients 1974–1998Acta Oncologica, 2004
- Surgical results for small cell lung cancer based on the new TNM staging systemThe Annals of Thoracic Surgery, 2000
- Results of operation without adjuvant therapy in the treatment of small cell lung cancerThe Annals of Thoracic Surgery, 1992
- Long-term survival in small cell carcinoma of the lungEuropean Journal of Cancer and Clinical Oncology, 1988